Inflammatory cytokine tumor necrosis factor α confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells

Neoplasia

Volumn 11, Issue 6, 2009, Pages 529-541

  Kwong, Joseph ^a,b,c,g   Franky, Leung Chan ^c   Wong, Kwong Kwok ^d   Birrer, Michael J ^e   Archibald, Kyra M ^b   Balkwill, Frances R ^b   Berkowitz, Ross S ^a,f   Mok, Samuel C ^a,d,f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BASEMENT MEMBRANE; CANCER INCIDENCE; CELL INVASION; CELL PROLIFERATION; CELL STRUCTURE; CHRONIC INFLAMMATION; CONTROLLED STUDY; EPITHELIUM CELL; EPITHELIUM TUMOR; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; OVARY; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPHEROID CELL;

EID: 66449125885     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09112     Document Type: Article

References (56)

1. Rosenthal A and Jacobs I (1998). Ovarian cancer screening. Semin Oncol 25, 315-325. (Pubitemid 28272605)
2. Bell D and Scully R (1991). Clinical Perspective on Borderline Tumors of the Ovary. New York, NY: Elsevier Science Publishing Co. Inc, pp. 119-133.
3. Seidman J, Russell P, and Kurman R (2002). Surface Epithelial Tumors of the Ovary. New York, NY: Springer, pp. 791-904.
4. Blaustein A (1981). Surface cells and inclusion cysts in fetal ovaries. Gynecol Oncol 12, 222-233. (Pubitemid 12251409)
5. Scully RE (1995). Pathology of ovarian cancer precursors. J Cell Biochem 23, 208-218. (Pubitemid 26032877)
6. Auersperg N, Wong AS, Choi KC, Kang SK, and Leung PC (2001). Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22, 255-288. (Pubitemid 32458162)
7. Kwong J, Choi HL, Huang Y, and Chan FL (1999). Ultrastructural and biochemical observations on the early changes in apoptotic epithelial cells of the rat prostate induced by castration. Cell Tissue Res 298, 123-136. (Pubitemid 29460511)
8. Giudice LC and Kao LC (2004). Endometriosis. Lancet 364, 1789-1799.
9. Merritt MA, Green AC, Nagle CM, and Webb PM (2008). Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 122, 170-176. (Pubitemid 350209992)
10. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, Morgan M, and Schlesselman JJ (2000). Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 11, 111-117. (Pubitemid 30112009)
11. Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, and Berchuck A (2006). Analgesic drug use and risk of ovarian cancer. Epidemiology 17, 104-107. (Pubitemid 43755787)
12. Lin WW and Karin M (2007). A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117, 1175-1183. (Pubitemid 46718402)
13. Yang WL, Godwin AK, and Xu XX (2004). Tumor necrosis factor-alpha-induced matrix proteolytic enzyme production and basement membrane remodeling by human ovarian surface epithelial cells: molecular basis linking ovulation and cancer risk. Cancer Res 64, 1534-1540. (Pubitemid 38235627)
14. Wu S, Boyer CM, Whitaker RS, Berchuck A, Wiener JR, Weinberg JB, and Bast RC Jr (1993). Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res 53, 1939-1944. (Pubitemid 23127128)
15. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayhan A, and Balkwill F (2007). The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 67, 585-592. (Pubitemid 46192196)
16. Tsao SW, Mok SC, Fey EG, Fletcher JA, Wan TS, Chew EC, Muto MG, Knapp RC, and Berkowitz RS (1995). Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res 218, 499-507.
17. Li NF, Broad S, Lu YJ, Yang JS, Watson R, Hagemann T, Wilbanks G, Jacobs I, Balkwill F, Dafou D, et al. (2007). Human ovarian surface epithelial cells immortalized with hTERT maintain functional pRb and p53 expression. Cell Prolif 40, 780-794. (Pubitemid 47416552)
18. Debnath J, Muthuswamy SK, and Brugge JS (2003). Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30, 256-268. (Pubitemid 36677560)
19. Livak KJ and Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-408. (Pubitemid 34164012)
20. Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, and Wilson JL (2005). The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 65, 10355-10362. (Pubitemid 41743728)
21. Radisavljevic SV (1977). The pathogenesis of ovarian inclusion cysts and cystomas. Obstet Gynecol 49, 424-429. (Pubitemid 8085289)
22. Murdoch WJ (1994). Ovarian surface epithelium during ovulatory and anovulatory ovine estrous cycles. Anat Rec 240, 322-326. (Pubitemid 24307253)
23. Slot KA, de Boer-Brouwer M, Voorendt M, Sie-Go DM, Ghahremani M, Dorrington JH, and Teerds KJ (2006). Irregularly shaped inclusion cysts display increased expression of Ki67, Fas, Fas ligand, and procaspase-3 but relatively little active caspase-3. Int J Gynecol Cancer 16, 231-239.
24. Deligdisch L, Einstein AJ, Guera D, and Gil J (1995). Ovarian dysplasia in epithelial inclusion cysts. A morphometric approach using neural networks. Cancer 76, 1027-1034.
25. Feeley KM and Wells M (2001). Precursor lesions of ovarian epithelial malignancy. Histopathology 38, 87-95. (Pubitemid 32193623)
26. Gusberg SB (1983). The diagnosis of gynecologic cancer. Cancer 51, 2477-2479.
27. Roland IH, Yang WL, Yang DH, Daly MB, Ozols RF, Hamilton TC, Lynch HT, Godwin AK, and Xu XX (2003). Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. Cancer 98, 2607-2623. (Pubitemid 37509524)
28. Blaustein A, Kaganowicz A, and Wells J (1982). Tumor markers in inclusion cysts of the ovary. Cancer 49, 722-726. (Pubitemid 12165429)
29. Cramer DW and Welch WR (1983). Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71, 717-721. (Pubitemid 14232385)
30. Levanon K, Crum C, and Drapkin R (2008). New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 26, 5284-5293.
31. Dubeau L (2008). The cell of origin of ovarian epithelial tumours. Lancet Oncol 9, 1191-1197.
32. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, and Williamson B (1975). An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72, 3666-3670.
33. Old LJ (1985). Tumor necrosis factor (TNF). Science 230, 630-632. (Pubitemid 16190956)
34. Balkwill F (2002). Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 13, 135-141.
35. Szlosarek PW and Balkwill FR (2003). Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 4, 565-573. (Pubitemid 38351714)
36. Szlosarek P, Charles KA, and Balkwill FR (2006). Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 42, 745-750.
37. Balkwill F (2006). TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 25, 409-416.
38. Komori A, Yatsunami J, Suganuma M, Okabe S, Abe S, Sakai A, Sasaki K, and Fujiki H (1993). Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. Cancer Res 53, 1982-1985. (Pubitemid 23145713)
39. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, et al. (1999). Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5, 828-831. (Pubitemid 29318619)
40. Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, and Fujiki H (1999). Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 59, 4516-4518. (Pubitemid 29428949)
41. Scott KA, Moore RJ, Arnott CH, East N, Thompson RG, Scallon BJ, Shealy DJ, and Balkwill FR (2003). An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol Cancer Ther 2, 445-451.
42. Babbar N and Casero RA Jr (2006). Tumor necrosis factor-alpha increases reactive oxygen species by inducing spermine oxidase in human lung epithelial cells: a potential mechanism for inflammation-induced carcinogenesis. Cancer Res 66, 11125-11130. (Pubitemid 46009938)
43. Yan B, Wang H, Rabbani ZN, Zhao Y, Li W, Yuan Y, Li F, Dewhirst MW, and Li CY (2006). Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation. Cancer Res 66, 11565-11570. (Pubitemid 46094163)
44. Bates RC and Mercurio AM (2003). Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell 14, 1790-1800. (Pubitemid 36583533)
45. Montesano R, Soulie P, Eble JA, and Carrozzino F (2005). Tumour necrosis factor alpha confers an invasive, transformed phenotype on mammary epithelial cells. J Cell Sci 118, 3487-3500. (Pubitemid 41246102)
46. Malik ST, Naylor MS, East N, Oliff A, and Balkwill FR (1990). Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer 26, 1031-1034.
47. Orosz P, Echtenacher B, Falk W, Ruschoff J, Weber D, and Mannel DN (1993). Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med 177, 1391-1398. (Pubitemid 23117129)
48. Orosz P, Kruger A, Hubbe M, Ruschoff J, Von Hoegen P, and Mannel DN (1995). Promotion of experimental liver metastasis by tumor necrosis factor. Int J Cancer 60, 867-871.
49. Egberts JH, Cloosters V, Noack A, Schniewind B, Thon L, Klose S, Kettler B, von Forstner C, Kneitz C, Tepel J, et al. (2008). Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 68, 1443-1450.
50. Naylor MS, Stamp GW, Foulkes WD, Eccles D, and Balkwill FR (1993). Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 91, 2194-2206. (Pubitemid 23141496)
51. Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS, Boyer CM, Peters WP, Weinberg JB, Berek JS, and Bast RC Jr (1992). Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. Am J Obstet Gynecol 166, 997-1007.
52. Marth C, Zeimet AG, Herold M, Brumm C, Windbichler G, Muller-Holzner E, Offner F, Feichtinger H, Zwierzina H, and Daxenbichler G (1996). Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer 67, 826-830. (Pubitemid 26348812)
53. Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan MM, Pyle L, Johnston SR, Ahern R, Smith IE, and Gore ME (2000). Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82, 812-817. (Pubitemid 30085231)
54. Madhusudan S, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, and Ganesan TS (2005). Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol 23, 5950-5959. (Pubitemid 46300212)
55. Acosta JC, O'Loghlen A, Banito A, Guijarro MV, Augert A, Raguz S, Fumagalli M, Da Costa M, Brown C, Popov N, et al. (2008). Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006-1018.
56. Scully RE (1977). Ovarian tumors. A review. Am J Pathol 87, 686-720.